| Texto completo | |
| Autor(es): Mostrar menos - |
Silva, Luan Cesar
;
Leite, Amanda Almeida
;
Borgato, Gabriell Bonifacio
;
Wagner, Vivian Petersen
;
Martins, Manoela Domingues
;
Loureiro, Felippe Jose Almeida
;
Lopes, Marcio Ajudarte
;
Santos-Silva, Alan Roger
;
Sperandio, Marcelo
;
Junior, Gilberto de Castro
;
Kowalski, Luiz Paulo
;
Squarize, Cristiane H.
;
Castilho, Rogerio Moraes
;
Vargas, Pablo Agustin
Número total de Autores: 14
|
| Tipo de documento: | Artigo Científico |
| Fonte: | AMERICAN JOURNAL OF CANCER RESEARCH; v. 13, n. 12, p. 13-pg., 2023-01-01. |
| Resumo | |
Despite many progresses in the development of new systemic therapies for oral squamous cell carcinoma (OSCC), the five-year survival rate of OSCC is low. The traditional chemotherapies approach (cisplatin - CDDP) shows some limitations like drug toxicity, limited efficacy, and drug resistance. Promising studies suggested OSCC cancer stem cells (CSC) presented resistance to CDDP. We have previously studied many targets, and we extensively showed the efficacy of the NF kappa B signaling and the role of histones acetylation, on different malignant tumors, including adenoid cystic carcinoma and mucoepidermoid carcinoma, but until then the effects of the NFkB inhibitor and histone deacetylase (HDAC) inhibitor on the biology of OSCC were not evaluated. Here we assessed the pharmacological inhibitor of NF kappa B emetine and HDAC inhibitor SAHA on the behavior of CSC derived from OSCC. Our data suggested that CDDP administration resulted in reduced viability of bulk OSCC cells and increased CSC. A single and isolated shot of emetine and SAHA were able to disrupt CSC by inhibiting the NF kappa B pathway and increasing the histone acetylation levels, respectively. Further, the combined administration of emetine and SAHA presented the same CSC disruption as seen in emetine alone. (AU) | |
| Processo FAPESP: | 21/13381-9 - Usando bibliotecas de pequenas moléculas e triagem de alto rendimento para identificar novos compostos inibitórios para o tratamento de carcinomas mucoepidermóides das glândulas salivares |
| Beneficiário: | Luan César da Silva |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |
| Processo FAPESP: | 19/06597-5 - Disrupção da resistência tumoral através de terapia direcionada a depleção de células tronco tumorais em Carcinomas Mucoepidermoides Salivares |
| Beneficiário: | Luan César da Silva |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 16/05710-4 - Disrupção da resistência tumoral através de terapia direcionada a depleção de células tronco tumorais em carcinomas espinocelulares de cabeça e pescoço |
| Beneficiário: | Pablo Agustin Vargas |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |